DK2481428T3 - Mmp-aktiverede karødelæggende midler - Google Patents
Mmp-aktiverede karødelæggende midler Download PDFInfo
- Publication number
- DK2481428T3 DK2481428T3 DK12160556.2T DK12160556T DK2481428T3 DK 2481428 T3 DK2481428 T3 DK 2481428T3 DK 12160556 T DK12160556 T DK 12160556T DK 2481428 T3 DK2481428 T3 DK 2481428T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- mmp
- vda
- cleavage site
- peptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (13)
1. Forbindelse eller farmaceutisk acceptabelt salt deraf, som omfatter et karødelæggende middel (VDA, vascular disrupting agent), som er et middel mod cancer, som er forbundet til et peptid, som omfatter et proteolytisk matrixmetalloproteinase (MMP)-spaltningssted, hvilket spaltningssted omfatter aminosyresekvensen -Arg-Ser-Cit-Gly-Hof-Tyr-Leu-.
2. Forbindelse ifølge krav 1, hvor forbindelsen har formlen (I) X-Y (I) hvor X er VDA’et; og Y er det proteolytiske MMP-spaltningssted.
3. Forbindelse ifølge krav 1 eller 2, hvor VDA'et har cytostatisk eller cytotoksisk effekt.
4. Forbindelse ifølge krav 1 eller 2, hvor VDA’et er i) en colchicinanalog, et colchicinoid, et combretastatin, et phenstatin, et podophyllotoksin, et steganacin, et amphethinil, et stilben eller et flavonoid, eller ii) et vineristin, et vinblastin, et vinflunin, et maytansinoid, phomopson A, et rhizoxin, et auristatin, en auristatinanalog eller et dolastatin.
5. Forbindelse ifølge et hvilket som helst af de foregående krav, som endvidere omfatter en capping-gruppe på peptidet, som omfatter et proteolytisk MMP-spaltningssted, hvilket forhindrer ikke-specifik nedbrydning af peptidet.
6. Forbindelse ifølge krav 5, hvor forbindelsen har formlen (II) X-Y-c (II) hvor X er VDA'et, Y er det proteolytiske MMP-spaltningssted, og c er en capping-gruppe valgt blandt simple sukkere, D-aminosyrer, prolin-iminosyrer, fluorescein og fluoresceinderivater.
7. Forbindelse ifølge et hvilket som helst af kravene 1-6, hvor et yderligere middel mod cancer er forbundet til det peptid, som omfatter et proteolytisk MMP-spaltningssted.
8. Forbindelse ifølge krav 7, hvor det yderligere middel mod cancer er valgt fra gruppen bestående af 5-fluoruracil, anthracyclin, doxorubicin, vincaalkaloid, taxan og et cytotoksisk nukleotid, og hvor midlet mod cancer fortrinsvis er doxorubicin.
9. Forbindelse ifølge krav 7 eller 8, hvor forbindelsen har formlen (VII) X-Y-Z (VII) hvor X er VDA’et, Y er det proteolytiske MMP-spaltningssted, og Z er midlet mod cancer.
10. Forbindelse eller farmaceutisk acceptabelt salt deraf ifølge et hvilket som helst af kravene 1-9 til anvendelse i medicin.
11. Farmaceutisk formulering, som omfatter en forbindelse ifølge et hvilket som helst af kravene 1-9 og mindst én/ét yderligere farmaceutisk acceptabel(t) excipiens, fortyndingsmiddel eller bærer.
12. Forbindelse eller farmaceutisk acceptabelt salt deraf ifølge et hvilket som helst af kravene 1-9 til anvendelse ved en fremgangsmåde til behandling af cancer, en inflammatorisk sygdom, hjerteinsufficiens eller sår.
13. Anvendelse af en forbindelse ifølge et hvilket som helst af kravene 1-9 til fremstilling af et lægemiddel til behandling af en sygdom eller tilstand valgt blandt cancer, en inflammatorisk sygdom, hjerteinsufficiens og sår.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0707034.5A GB0707034D0 (en) | 2007-04-12 | 2007-04-12 | Compounds |
EP08718877.7A EP2134372B1 (en) | 2007-04-12 | 2008-03-27 | Mmp activated vascular disrupting agents |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2481428T3 true DK2481428T3 (da) | 2016-06-13 |
Family
ID=38116587
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12160556.2T DK2481428T3 (da) | 2007-04-12 | 2008-03-27 | Mmp-aktiverede karødelæggende midler |
DK12160565.3T DK2481429T3 (da) | 2007-04-12 | 2008-03-27 | Mmp-14-specifik spaltningssekvens |
DK08718877.7T DK2134372T3 (da) | 2007-04-12 | 2008-03-27 | MMP-aktiverede karødelæggende midler |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12160565.3T DK2481429T3 (da) | 2007-04-12 | 2008-03-27 | Mmp-14-specifik spaltningssekvens |
DK08718877.7T DK2134372T3 (da) | 2007-04-12 | 2008-03-27 | MMP-aktiverede karødelæggende midler |
Country Status (16)
Country | Link |
---|---|
US (4) | US8691751B2 (da) |
EP (4) | EP2481428B1 (da) |
JP (4) | JP5537413B2 (da) |
CY (1) | CY1120368T1 (da) |
DK (3) | DK2481428T3 (da) |
ES (3) | ES2573228T3 (da) |
GB (1) | GB0707034D0 (da) |
HK (2) | HK1174534A1 (da) |
HR (1) | HRP20181043T1 (da) |
HU (3) | HUE027528T2 (da) |
LT (1) | LT2481429T (da) |
PL (3) | PL2134372T3 (da) |
PT (1) | PT2481429T (da) |
SI (1) | SI2481429T1 (da) |
TR (1) | TR201807811T4 (da) |
WO (1) | WO2008125800A2 (da) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0707034D0 (en) * | 2007-04-12 | 2007-05-23 | St Andrews The | Compounds |
GB0819287D0 (en) * | 2008-10-22 | 2008-11-26 | Univ Bradford | Compounds |
GB2516882A (en) * | 2013-08-02 | 2015-02-11 | Univ Bradford | Tumour-targeted theranostic |
US9169337B2 (en) | 2014-03-12 | 2015-10-27 | Chevron Phillips Chemical Company Lp | Polymers with improved ESCR for blow molding applications |
GB2545169B (en) * | 2015-12-01 | 2019-10-09 | Ellipses Pharma Ltd | Taxane Prodrug Comprising A Membrane Type Matrix Metalloproteinase Cleavage Site |
JP7360169B2 (ja) | 2017-07-07 | 2023-10-12 | カトリック ユニヴェルシテット ルーヴェン | 無血管性または乏血管性微小腫瘍の治療 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2401873A1 (en) | 2000-03-15 | 2001-09-20 | Robert A. Copeland | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
GB0018240D0 (en) * | 2000-07-25 | 2000-09-13 | Pharmacia & Upjohn Spa | Polymeric conjugates of antitumor agents |
GB0105929D0 (en) * | 2001-03-09 | 2001-04-25 | Btg Int Ltd | Physiologically activated prodrugs |
AU2003263964C1 (en) | 2002-07-31 | 2010-08-19 | Seagen Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US20050106100A1 (en) | 2003-09-03 | 2005-05-19 | Harris Thomas D. | Compounds containing matrix metalloproteinase substrates and methods of their use |
US8420603B2 (en) | 2004-05-14 | 2013-04-16 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
EP1853631B1 (en) * | 2005-01-24 | 2016-03-09 | Board of Regents, The University of Texas System | Fc FUSION CONSTRUCTS BINDING TO PHOSPHATIDYLSERINE AND THEIR THERAPEUTIC USE |
EP1862470A4 (en) | 2005-02-25 | 2010-04-21 | Univ Hokkaido Nat Univ Corp | ELEMENT RETAINED IN BLOOD SHOWING SELECTIVE DEGRADABILITY IN TUMOR TISSUE |
US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
GB0707034D0 (en) * | 2007-04-12 | 2007-05-23 | St Andrews The | Compounds |
GB0819287D0 (en) | 2008-10-22 | 2008-11-26 | Univ Bradford | Compounds |
GB2516882A (en) | 2013-08-02 | 2015-02-11 | Univ Bradford | Tumour-targeted theranostic |
-
2007
- 2007-04-12 GB GBGB0707034.5A patent/GB0707034D0/en not_active Ceased
-
2008
- 2008-03-27 HU HUE08718877A patent/HUE027528T2/en unknown
- 2008-03-27 ES ES08718877.7T patent/ES2573228T3/es active Active
- 2008-03-27 ES ES12160556.2T patent/ES2573682T3/es active Active
- 2008-03-27 PL PL08718877.7T patent/PL2134372T3/pl unknown
- 2008-03-27 HU HUE12160565A patent/HUE038633T2/hu unknown
- 2008-03-27 EP EP12160556.2A patent/EP2481428B1/en active Active
- 2008-03-27 SI SI200831959T patent/SI2481429T1/en unknown
- 2008-03-27 PT PT121605653T patent/PT2481429T/pt unknown
- 2008-03-27 DK DK12160556.2T patent/DK2481428T3/da active
- 2008-03-27 HU HUE12160556A patent/HUE029080T2/en unknown
- 2008-03-27 TR TR2018/07811T patent/TR201807811T4/tr unknown
- 2008-03-27 US US12/595,482 patent/US8691751B2/en active Active
- 2008-03-27 DK DK12160565.3T patent/DK2481429T3/da active
- 2008-03-27 JP JP2010502559A patent/JP5537413B2/ja not_active Expired - Fee Related
- 2008-03-27 WO PCT/GB2008/001043 patent/WO2008125800A2/en active Application Filing
- 2008-03-27 LT LTEP12160565.3T patent/LT2481429T/lt unknown
- 2008-03-27 PL PL12160556.2T patent/PL2481428T3/pl unknown
- 2008-03-27 DK DK08718877.7T patent/DK2134372T3/da active
- 2008-03-27 PL PL12160565T patent/PL2481429T3/pl unknown
- 2008-03-27 ES ES12160565.3T patent/ES2683168T3/es active Active
- 2008-03-27 EP EP12160565.3A patent/EP2481429B1/en active Active
- 2008-03-27 EP EP18156526.8A patent/EP3348282A1/en not_active Withdrawn
- 2008-03-27 EP EP08718877.7A patent/EP2134372B1/en active Active
-
2013
- 2013-01-31 HK HK13101399.0A patent/HK1174534A1/zh not_active IP Right Cessation
- 2013-12-17 US US14/109,333 patent/US9358303B2/en not_active Expired - Fee Related
-
2014
- 2014-04-25 JP JP2014090991A patent/JP5931952B2/ja not_active Expired - Fee Related
- 2014-04-25 JP JP2014090990A patent/JP5911908B2/ja not_active Expired - Fee Related
-
2016
- 2016-04-27 JP JP2016088836A patent/JP6170590B2/ja not_active Expired - Fee Related
- 2016-05-06 US US15/148,368 patent/US9956296B2/en active Active
-
2018
- 2018-03-16 US US15/923,564 patent/US10556014B2/en not_active Expired - Fee Related
- 2018-06-27 CY CY20181100663T patent/CY1120368T1/el unknown
- 2018-07-05 HR HRP20181043TT patent/HRP20181043T1/hr unknown
-
2019
- 2019-01-16 HK HK19100772.3A patent/HK1258466A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10912839B2 (en) | Methods of treating cancer using compounds containing a vascular disrupting agent | |
US10556014B2 (en) | Compounds containing a vascular disrupting agent |